本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline are presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. Late-Breaking Research: Experimental and Molecular Therapeutics 1 Topic: IBI3001: a potentially first-in-class site-specific glycan-conjugated B7-H3/EGFR bispecific ADC for multiple solid tumorsAbstract Number: LB055Presentation Form: PosterPresentation Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He IBI3001 is a potentially first-in-class bispecific ADC against B7-H3 and EGFR that is site-specifically glycan-conjugated using the clinically validated SYNtecanE® platform. IBI3001 has multiple anti-tumor mechanisms of action: (1) enhanced EGFR signaling blockade; (2) EGFR- and B7-H3-aided payload internalization and cytotoxicity; and (3) potent bystander killing effects of ADC. The optimized B7-H3 arm not only enhances the EGFR signaling blockade but also reduces EGFR on-target toxicities. IBI3001 showed strong anti-tumor efficacy in vitro and in vivo across multiple solid tumors and is well tolerated with the therapeutic index at 40. Topic: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumorsAbstract Number: LB056Presentation Form: PosterPresentation Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He IBI334 is an afucosylated bispecific antibody against B7-H3 and EGFR that is constructed using Innovent's proprietary Innobody platform. With the aid of B7-H3, IBI334 showed better tumor growth inhibition in vitro and in vivo than EGFR monoclonal antibody and c-met/EGFR bispecific antibody benchmarks. IBI334 has a favorable safety profile with the highest non-severely toxic dose (HNSTD) in cynomolgus monkeys at 120 mg/kg and a large therapeutic window of > 200 folds. As a promising bispecific antibody against multiple solid tumors, IBI334 is currently under clinical evaluation. Topic: Discovery and preclinical characterization of IBI343, a site-specific glycan-conjugated anti-Claudin18.2 ADC for treating solid tumorsAbstract Number: LB057Presentation Form: PosterPresentation Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He IBI343 is a potentially first-in-class anti-Claudin 18.2 ADC that is site-specifically glycan-conjugated to cytotoxin exatecan via Synaffix's GlycoConnect® technology. It demonstrated Claudin 18.2-specific in vitro cytotoxicity on a series of cancer cell lines at varying levels of target expression, and potent in vivo efficacy in multiple xenograft models. The glycan-based conjugation technology leads to enhanced stability of the ADC molecule. IBI343 displayed good safety profile in GLP toxicology study in rhesus monkey and was well tolerated up to 30 mg/kg. IBI343 has favorable pre-clinical efficacy and safety, and it is currently in preparation for Phase 3 clinical trial for Claudin-18.2-positive HER2-negative gastric cancer. Dr. Kaijie He, Vice President of Innovent, stated: "We are pleased that the pre-clinical studies of our novel anti-cancer drugs are accepted for Late-Breaking Research poster presentation at the 2024 AACR conference. This is the result of dedicated work from scientists at Innovent Academy with the aim to tackle cancers with innovative drugs that are more effective and safer. With careful design and optimization, our molecules can achieve favorable therapeutic windows of 40 to more than 200 times. We look forward to their performance in clinical settings and hope that these innovations can eventually benefit cancer patients." Poster Session: Immunology - Single Target and Bispecific Antibodies Topic: A novel TROP2-targeted immune stimulating antibody conjugate (ISAC) with potent anti-tumoral activity and acceptable safetyAbstract Number: 2718Presentation Form: PosterPresentation Time: Monday Apr 8, 2024 1:30 PM - 5:00 PMLocation: Poster Section 6Poster Board Number: 9Presenting Author: Dr. Huizhong Xiong Immune stimulating antibody conjugates (ISACs) are a unique class of ADC in which antibodies recognizing tumor antigens are conjugated with immune agonists. ISACs target tumor tissue and specifically activate intra-tumoral myeloid cells, unleashing downstream immune response. Like the other immune agonists, balance between efficacy and safety remains a challenge for ISACs. Here we describe a potential first-in-class TROP2 ISAC with rationally selected antibody and TLR7/8 agonist linker-payload. The anti-TROP2 antibody elicited robust ADCP of TROP2+ tumor cells by macrophages. In-vitro, TROP2 ISAC mildly activated myeloid cells only in the presence of TROP2+ tumor cells. In-vivo, the molecule potently suppressed tumor growth in different TROP2+ xenograft tumors, and effectively enhanced killing of an ADC. In terms of safety, the ISAC was tolerated in both WT and hTROP2KI mice, and, importantly, in monkeys. Taken together, our data demonstrate a novel TROP2 ISAC with outstanding efficacy and manageable safety profile, which may benefit patients with TROP2+ tumors. Poster Session: Immunology - Immune Modulation Employing Agonist or Co-Stimulatory Approaches Topic: Tumor targeted-CD28 bispecific antibody with optimized potency, robust anti-tumoral activity and stringent CD3-dependenceAbstract Number: 5295Presentation Form: PosterPresentation Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PMLocation: Poster Section 3Poster Board Number: 4Presenting Author: Dr. Huizhong Xiong We reported a rationally screened CD28 agonist antibody and its PSMAxCD28 bispecific format, IAR038. IAR038 has minimal activity in the absence of CD3, even under stringent conditions, different from benchmark antibody in clinical development. It demonstrated moderate activity in vitro in a CD3-dependent and PSMA-dependent manner. Notably, IAR038 elicited superior tumor killing in vivo and combined effectively with anti-PD1 antibody. In addition, it had an improved half-life compared with the Benchmark antibody. These features may translate to a wider therapeutic window and improved safety for CRPC patients. Dr. Huizhong Xiong, Senior Director of Immunology of Innovent, stated: "We keep pushing for deeper understanding and more rational design of agonistic and costimulatory molecules. Our work on tumor targeted TLR7/8 agonist and tumor targeted CD28 antibody demonstrates the capability of our biology-driven drug development to achieve better balance between efficacy and safety, made possible by our advanced technology platforms." About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin (R&D Code: APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development (EED) inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). This year's AACR annual meeting will be held from April 5-10 2024, in San Diego, California, USA. "We are pleased to present the preclinical research data of four assets in our pipeline at the AACR 2024. The results provided essential support for the potential clinical development and therapeutic combinations of these compounds in SDH-deficient neoplasms, prostate cancer, and ovarian cancer," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Moving forward, we will continue to advance these programs toward the clinical stage in order to bring more treatment options to patients in need." The details of these three preclinical studies are as follows: Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms Abstract#: 1971 Time: Monday April 8, 2024, 9:00 AM - 12:30 PM (Pacific Time) Introduction: Succinate dehydrogenase (SDH) – deficient (dSDH) neoplasms are identified by the loss of immunohistochemical expression of SDHB due to the bi-allelic inactivation of any of the four components of mitochondrial SDH complex (SDH A-D). Succinate accumulation, due to SDH deficiency, is involved in tumorigenesis of different types of cancers including gastrointestinal stromal tumor (GIST), paraganglioma, pheochromocytoma, renal cell carcinoma, pituitary adenomas, and pancreatic neuroendocrine tumors. The prognosis of patients with dSDH neoplasia, especially GIST, is poor and approved tyrosine kinase inhibitors (TKIs) have limited efficacy. There is a high unmet medical need for these patients. Olverembatinib, a novel multi-kinase inhibitor, targets a broad spectrum of kinases and has demonstrated promising efficacy in dSDH GIST patients in an ongoing phase I clinical trial. In this study, we assessed antitumor effects of olverembatinib in preclinical models of dSDH cancers and dSDH GIST primary tumor cells, and explored potential mechanisms of action. Conclusions: Olverembatinib showed superior anti-tumor activity in dSDH cell lines in vitro and human dSDH GIST primary tumor cells ex vivo. Olverembatinib, as a multi-target kinase inhibitor, exerted antitumor effects by modulating multiple signaling pathways including hypoxia, angiogenesis, apoptosis, proliferation, and survival, which are involved in tumorigenesis of dSDH cancers. Olverembatinib demonstrated more potent in vivo antitumor activity in mice bearing PC12#5F7 (SDHB KD) xenograft tumors than other TKIs. Western blot analysis in tumor tissues collected from mice further confirmed the modulation of the signal pathways by olverembatinib observed in cell lines. In summary, the results provide a rationale for future clinical development of olverembatinib in dSDH cancers. Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa) Abstract#: 3223 Time: Monday April 8, 2024, 1:30 PM - 5:00 PM (Pacific Time) Introduction: Prostate cancer (PCa) is one of the most frequently diagnosed malignancies among elderly males. Androgen deprivation therapy (ADT) with or without androgen receptor (AR) inhibitors is widely used as initial treatment for advanced PCa. However, most ADT-treated patients eventually develop castration-resistant prostate cancer (CRPC), which is in urgent need of novel therapies. Polycomb repressive complexes 2 (PRC2) dysregulation is common in PCa and correlates with poor prognosis. PRC2 mediates histone H3 lysine 27 tri-methylation (H3K27me3), a repressive epigenetic marker for gene transcription. embryonic ectoderm development (EED), a PRC2 core component, is crucial for histone methyltransferase activity through direct binding to H3K27me3. MDM2, a negative regulator of the tumor suppressor p53, is frequently amplified or overexpressed in PCa, and associated with poor clinical outcomes and metastasis. The aim of this study was to evaluate antitumor activity and molecular mechanisms of the investigational, clinical-stage EED inhibitor APG-5918/EEDi-5273 and MDM2 selective inhibitor alrizomadlin (APG-115) in PCa preclinical models Conclusions: In PCa preclinical models, the combination of APG-5918 and alrizomadlin synergistically inhibited cellular proliferation and induced cellular apoptosis. APG-5918 in combination with alrizomadlin synergistically enhanced antitumor activity in PCa xenograft models in vivo. Mechanistically, PD analysis revealed that APG-5918 downregulated the oncogenic DNA methylation factors (UHRF1, DNMT1) and histone methylation marker H3K27me3. Alrizomadlin markedly downregulated UHRF1 and DNMT1, and upregulated p53 and p21 expression. Combined treatment further enhanced downregulation of DNMT1, UHRF1, cell cycle pathway proteins (pRb, CDK6), antiapoptotic protein MCL-1, and synergistically increased cleavage of PARP-1, a marker of apoptosis. Therefore, the findings provide a scientific rationale for future clinical development of APG-5918 and alrizomadlin to treat patients with PCa. APG-2449, a novel focal adhesion kinase (FAK) inhibitor, inhibits metastasis and enhances the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC) Abstract#: 4569 Time: Tuesday April 9, 2024, 9:00 AM - 12:30 PM (Pacific Time) Introduction: Ovarian cancer is among the leading causes of cancer-related death in women, and most cases are diagnosed at later stages with distant metastasis. FAK overexpression or activation occurs in a substantial proportion of epithelial ovarian cancers (EOCs) and is predictive of poor clinical outcomes. FAK plays an important role in cell migration and chemoresistance, rendering FAK inhibition a promising treatment approach to reduce metastasis of tumor cells and sensitize them to chemotherapy. FAK is therefore emerging as a potential treatment target. The aim of this study was to evaluate the antitumor efficacy of investigational APG-2449, a novel FAK inhibitor, combined with PLD, a commonly used chemotherapy, in relapsed or refractory ovarian cancer. Conclusions: APG-2449 combined with doxorubicin showed synergistic antiproliferative effects in both platinum-resistant and platinum-sensitive ovarian cancer cell lines. FAK inhibition via APG-2449 alone attenuated migration of ovarian cancer cells in a dose-dependent manner. APG-2449 in combination with PLD showed enhanced antitumor activity in platinum-resistant OVCAR-3 ovarian cancer CDX model. The combination regimen prolonged ascites-free and survival times in the ID8-Luc peritoneal syngeneic model. These promising results support the future clinical development of this combination treatment for ovarian cancer. About Ascentage Pharma Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients. Forward-Looking Statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States. The posters showcased four of Antengene's high-potential emerging programs, including ATG-042, tracking to a H1 2025 IND filing; ATG-022, in Phase II dose expansion studies in China and Australia; AnTenGagerTM platform, Antengene's proprietary T-cell engager (TCE) platform; and ATG-102, which could be the first IND candidate from AnTenGagerTM platform. ATG-042, an oral small molecule MTAPnull-selective PRMT5 inhibitor holding the promise as a best-in-class drug. Study results showed that ATG-042 has the potential to elegantly target tumor cells while sparing healthy cells, with an attractive developability profile. ATG-022 is an Claudin 18.2 antibody-drug conjugate. The detailed updated data of the Claudin 18.2 (CLDN18.2) companion diagnostic antibody candidate for ATG-022 showed that the antibody has higher sensitivity compared to commercially available kits. AnTenGagerTM, Antengene's proprietary TCE platform with the ability to induce target-dependent T-cell activation, has potent anti-tumor effects and lower risk of cytokine release syndrome (CRS). ATG-102, a LILRB4 x CD3 TCE, is being developed for the treatment of acute myeloid leukemia (AML). Details of the posters: ATG-042 (MTAPnull-selective PRMT5 Inhibitor) Title: Preclinical characterization of ATG-042, a novel MTAPnull-selective PRMT5 inhibitor Abstract: 4592 Session Category: Experimental and Molecular Therapeutics Session Title: HDAC and Methyltransferase Inhibitors Date: April 9, 2024 Time: 9:00 AM - 12:30 PM (Pacific Time) 12:00 AM - 3:30 AM, April 10, 2024 (Beijing Time) Location: Poster Section 24 This preclinical study was designed to test the in vitro/in vivo efficacy, and preclinical pharmacokinetic (PK) properties of ATG-042. According to the results, ATG-042 demonstrated a potent and selective inhibitory effect on the proliferation of MTAP knockout cells, showed high permeability, good metabolic stability, a low risk of drug-drug interaction (DDI), and high oral bioavailability. Importantly, ATG-042 demonstrated good brain penetrability. In CDX models, ATG-042 also potently and selectively inhibited tumor growth without inducing weight loss. These data suggest that ATG-042 is an orally administered, MTAPnull-selective PRMT5 inhibitor with potent efficacy against MTAP-null tumors, as well as demonstrating good tolerability and favorable preclinical PK profiles. Companion Diagnostic Antibody for ATG-022 (Claudin 18.2 ADC) Title: Development of a novel companion diagnostic immunohistochemistry antibody for Claudin 18.2-targeted therapies Abstract: 1032 Session Category: Clinical Research Session Title: Diagnostic Biomarkers 1 Date: April 7, 2024 Time: 1:30 PM - 5:00 PM (Pacific Time) 4:30 AM - 8:00 AM, April 8, 2024 (Beijing Time) Location: Poster Section 42 Despite the substantial correlation between the expression of CLDN18.2 and the efficacy of therapies targeting CLDN18.2, no companion diagnostic (CDx) antibodies specific to CLDN18.2 have been approved to date. This poster presents the discovery and validation of a novel, highly sensitive immunohistochemistry (IHC) antibody that selectively identifies CLDN18.2. According these data, the monoclonal antibody (mAb) clone 43F11 showed positive cell surface IHC staining on CLDN18.2-expressing cells following fixation but demonstrated no staining on CLDN18.1-expressing cells. Moreover, the 43F11 antibody accurately identified the expression level of CLDN18.2 in an IHC assay, utilizing tumor tissues and patient-derived xenograft (PDX) samples with predetermined expression levels of CLDN18.2. When compared to the commercially available IHC antibody EPR19202, the 43F11 antibody demonstrated greater sensitivity, enabling positive staining on cancer tissues with significantly lower expression levels of CLDN18.2. These data suggest that the 43F11 antibody possesses superior sensitivity compared to the benchmark antibody and has the potential to serve as an effective patient stratification tool. AnTenGagerTM Platform Title: AnTenGagerTM, a novel "2+1" T cell engager platform, enables conditional T cell activation with reduced risk of CRS Abstract: 6343 Session Category: Clinical Research Session Title: Antibodies 2 Date: April 9, 2024 Time: 1:30 PM - 5:00 PM (Pacific Time) 4:30 AM - 8:00 AM, April 10, 2024 (Beijing Time) Location: Poster Section 41 This poster presents an in-depth overview of the design and mechanism of action for the proprietary AnTenGagerTM T cell engager (TCE) platform. These TCEs are specifically designed to produce an anti-cancer effect with a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for use in solid tumors. AnTenGagers TCE constructs are designed to induce cytotoxicity by forming a T cell receptor (TCR)-independent immune synapse. AnTenGagers do this by simultaneously binding tumor associated antigens (TAAs) on cancer cells and specific conformational epitopes on CD3+ T-cells. Presented data show that AnTenGagers are able to effectively bind to specific CD3 confirmational epitopes and demonstrate higher cytotoxicity compared to benchmark compounds. AnTenGagers are compatible with a range of TAAs, and that AnTenGagers have improved cytotoxicity compared to benchmark compounds, as demonstrated in cellular assays and a murine myeloma model. Data from the murine models also showed that AnTenGagers resulted in significantly lower concentrations of pro-inflammatory cytokines, further supporting a lower risk of CRS. AnTenGagers also have good "developability" properties based on good stability under stress conditions. Together, these data support the potential for AnTenGagers to be used in solid tumors, based on their ability to simultaneously bind TAAs and specific CD3+ confirmational epitopes, resulting in higher TAA-dependent cytotoxicity compared to benchmarks and the reduced risk of CRS, opening the door to a broad new class of cancer therapies. ATG-102 (LILRB4 x CD3 T Cell Engager) Title: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two non-overlapping epitopes of LILRB4, for the treatment of monocytic AML Abstract: 2372 Session Category: Clinical Research Session Title: Antibodies 1 Date: April 8, 2024 Time: 9:00 AM - 12:30 PM (Pacific Time) 12:00 AM - 3:30 AM, April 9, 2024 (Beijing Time) Location: Poster Section 38 The use of TCEs to treat AML (acute myeloid leukemia) has been limited the difficulty in identifying specific antigens that are expressed on AML and leukemic stem cells but not normal hematopoietic stem cells. The preferential expression of LILRB4 on M4/M5 subtype acute myeloid leukemia (AML) cells renders it a highly attractive target for the treatment of AML. These data show that an AnTenGagerTM based TCE, which binds to two distinct epitopes of the LILRB4 receptor, can induce potent T-cell dependent cellular cytotoxicity (TDCC) to produce potent anti-tumor efficacy in vitro and in vivo. The poster outlines the design and structural characteristics of ATG-102 comprised of two LILRB4 epitopes and an anti-CD3 single chain fragment variable (scFv) inserted in the hinge region on one of the LILRB4 heavy chains. Characterization data include: -Binding epitope and affinity studies showing that ATG-102 binds to the target TAA epitopes as well as conformational CD3 epitopes. -T cell binding and T-cell dependent cytotoxicity assays show that compared to the benchmark, ATG-102 demonstrated less non-specific T cell binding or activation, whilst inducing more potent TDCC against LILRB4+cells and enhanced in vivo anti-AML efficacy. These data highlight the structural characteristics of ATG-102 and demonstrate potent in vitro and in vivo anti-tumor efficacy which support further clinical evaluation of ATG-102. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 11 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
HONG KONG SAR - Media OutReach Newswire - 5 April 2024 - CK Life Sciences Int’l., (Holdings) Inc. will be presenting new data from its cancer vaccine research pipeline at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, USA. Two posters will highlight data from preclinical studies of 2 investigational cancer vaccines, targeting the KRAS (Kirsten rat sarcoma virus) and PD-L1 (programmed cell death ligand 1) proteins, respectively. The KRAS protein, frequently mutated in various cancers, is a key regulator of cell growth and survival, driving tumor development by promoting uncontrolled cell proliferation and resistance to treatment. The PD-L1 protein represents one of the most important immune checkpoint proteins highly expressed on cancer cells to limit T-cell activation in the tumor microenvironment. In addition, CK Life Sciences and its research collaborator, XtalPi, will be presenting a poster showcasing their Artificial Intelligence (AI)-empowered platform for designing cancer vaccines. “The preclinical efficacy results of our investigational cancer vaccines targeting KRAS and PD-L1 proteins are promising, and we hope to advance these and other vaccines into clinical development in the future. We are also thrilled about the progress made in our research collaboration with XtalPi to develop an AI platform aimed at better predicting immunogenicity and designing cancer vaccines that are more likely to be effective,” said Melvin Toh, Vice President & Chief Scientific Officer at CK Life Sciences. DETAILS ON POSTER PRESENTATIONS: • Abstract 4111: Multi-peptide cancer vaccines targeting KRAS induce significant anti-tumor efficacy Authors: Chi Han Samson Li, Melvin Toh Session Date and Time: Tuesday, April 9th, 9:00 AM - 12:30 PM Pacific Standard Time KRAS epitopes harbouring mutations are strong neoantigens to which the immune system generates anti-tumor effects. Evidence suggests that CD4 T cell activity plays a critical role in augmenting the cytotoxic effect of CD8 T cells. By selecting MHC II hotspots via multiple epitope prediction algorithms, we designed and synthesized 8 long peptides, covering mutant and/or wild-type (WT) regions of human KRAS protein, that activate both CD4 and CD8 T cells to kill KRAS-driven cancer cells. In addition, the corresponding keyhole limpet hemocyanin (KLH) conjugated peptides were also generated. Different combinations of peptides were immunised into Balb/c mice before determining the immune response by mouse interferon γ (mIFNγ) ELISPOT assay. T cell responses were observed in two peptide mixes with or without KRAS G12D mutation, suggesting that both mutant-harbouring peptide and WT peptides were immunogenic. We found that KLH-conjugated and CpG+alum adjuvanted peptides elicited stronger immune responses than naked and CFA/IFA adjuvanted peptides. Immunisation of KRAS naked peptide and KLH-conjugated peptide vaccines in a CT26 syngeneic mouse preventive colorectal cancer model significantly inhibited tumor growth by 51.2% (****p < 0.0001) and 44.7% (***p < 0.001) respectively, compared to control. mIFNγ ELISPOT assay showed that the tumor inhibitory effect was attributed to the activation of antigen-specific T cell response of the vaccines. • Abstract 4106: A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model Authors: Kenneth Nansheng Lin, Melvin Toh Session Date and Time: Tuesday, April 9th, 9:00 AM - 12:30 PM Pacific Standard Time We developed a blend of four novel synthetic peptide vaccines each containing one PD-L1 T-cell epitope with individual covalent conjugation of the carrier protein, KLH, to break immune tolerance towards self-molecules. The four PD-L1 epitopes ranged from 30 to 40 amino acids in length, targeting different domains of mouse PD-L1 protein. The KLH-conjugated peptide vaccines were formulated with CpG+alum for animal immunisation. These adjuvanted synthetic long PD-L1 peptide vaccines were highly immunogenic in a syngeneic BALB/c mouse model for a cell-mediated immune response. The vaccine formulation was well tolerated, with no evidence of toxicity and autoimmunity. In vivo administration of the vaccine formulation elicited a positive PD-L1-specific T cell response in splenocytes with an IFN-γ ELISPOT assay. Moreover, in vivo vaccination of these PD-L1 peptide vaccines in a CT26 syngeneic mouse preventive colorectal cancer model exhibited anti-tumor activity, with a 54% tumor growth inhibition (p<0.001) in tumor volume compared to that of the adjuvant-control group at the end of the study. • Abstract 3525: Towards the efficient design of shared neoantigen peptide cancer vaccines using artificial intelligence Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Tianyuan Wang, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Ruohan Zhu, Yalong Zhao, Samson Li, Melvin Toh, Lipeng Lai Session Date and Time: Monday, April 8th, 1:30 PM - 5:00 PM Pacific Standard Time The accurate prediction of immunogenicity of cancer vaccines remains elusive. We developed new models that predict the probability of a given peptide derived from the protein of interest to be presented by MHC-I or MHC-II. For MHC-I antigen presentation model development, over 17 million entries in the dataset were collected from published literature and available databases, e.g., IEDB, with peptide lengths ranging from 8 to 11. The peptides were restricted to 150 unique MHC-I alleles. Similarly, ~4 million entries with peptide lengths ranging from 13 to 21 were collected for MHC-II antigen presentation model development, and the peptides were restricted to 19 unique MHC-II alleles. To develop advanced antigen presentation models, a language model was chosen as the backbone network and contrast learning was used to better discriminate the peptide-MHC match versus mismatch. Overall, both MHC-I and MHC-II presentation models were constructed with about 30 million parameters. To validate algorithm prediction accuracy and peptide immunogenicity, 28 predicted patentable peptides derived from mutated TP53 protein were synthesized and their binding to respective common HLA alleles was validated using surface plasmon resonance. We found that >80% of the peptides displayed binding affinities stronger than the positive control, suggesting that AI significantly improves neoantigen peptide vaccine design. Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation. Hashtag: #CKLifeSciences #CancerVaccines #R&D #AACRhttps://www.ck-lifesciences.com/eng/index.phpThe issuer is solely responsible for the content of this announcement.CK Life Sciences Int'l., (Holdings) Inc.CK Life Sciences Int’l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in, products and assets which fall into three core categories: nutraceuticals, pharmaceuticals & diagnostics, and agriculture-related. Regarding pharmaceutical research and development, CK Life Sciences’ operations are focused on conducting research and development into cancer vaccines and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com. DISCLAIMER This press release may contain forward-looking statements regarding the Group's research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information. Copyright ©2024 CK Life Sciences Int'l., (Holdings) Inc.. All rights reserved.
SHENZHEN, China, April 3, 2024 /PRNewswire/ -- In an era where digital storytelling is integral to our daily lives, global smartphone maker vivo champions the belief that everyone holds the potential to be a creator. The company has been at the forefront of the transformation of smartphones into powerful tools for creativity and professional-grade photography. Making great photography accessible to everyone, to all creators, regardless of their skills or knowledge, to capture high-quality images and videos on their smartphones is a testament to vivo's commitment to empowering creativity in everyday life. From the renowned X series flagships to V series portrait-powerhouse smartphones, vivo's advanced imaging technologies are designed to deliver rich and diverse visual expressions. With each iteration, vivo brings professional-grade imaging capabilities to capture breathtaking landscapes or precious moments with stunning visuals. A Look into vivo's Imaging Evolution vivo's relentless pursuit to make professional-level photography more accessible can be traced back to its very beginnings. Focusing on night photography, portraits, motion stabilization, zoom, and video capabilities, vivo has consistently pushed boundaries guided by a deep understanding of consumer needs and bolstered by groundbreaking software and hardware technologies. vivo is the company that introduced the industry-leading Gimbal Camera System, modeled after a full-size professional gimbal, rethinking how smartphones handle image stabilization. This system allowed users to experience shake-free capture without using an external gimbal, setting the stage for powerful night and low-light photography. Continuing its innovation streak, vivo introduced the V1 chip, its first dedicated ISP chip, further elevating its technological prowess. The chip allowed for noise reduction and smoother visuals using AI, ensuring uncompromised image quality even in low light. Introduced globally with X70 series for the first time, vivo has continued to improve this dedicated chip with every new generation. vivo and ZEISS: A Partnership Rooted in Innovation vivo's mission to empower all creators with professional imaging capabilities took a significant step forward in 2020 when the company entered a strategic partnership with ZEISS, a global leader in optics and optoelectronics. This collaboration was built with the long-term strategic intention to play to each other's strengths and further advance mobile photography technology. This includes the establishment of the vivo ZEISS Imaging Lab, a joint R&D program made to innovate mobile imaging technology for vivo's flagship smartphones. The partnership began in 2020, and it was clear from the start that this collaboration was not simply a matter of combining two brands or about utilizing a single technology. Instead, it was made to be a deep and comprehensive joint R&D effort that would require long-term commitment on both sides. The joint R&D efforts have already resulted in several key features that have improved the mobile imaging experience for users. One example is the ZEISS Biotar Style Bokeh. Developed by ZEISS in the mid-1930s, the Biotar lens is known by photographers for its unique swirly bokeh. Thanks to the joint efforts by vivo and ZEISS, this iconic bokeh effect is now also available on vivo smartphones, allowing all photography enthusiasts to work with this popular style. With the rapid development of multimedia and short videos, vivo recognizes that users' demand for videography is growing substantially. The joint success of the collaboration between vivo and ZEISS in cinematic lenses have allowed the companies to develop lens features that can recreate the characteristics of iconic ZEISS lenses in software, resulting in stylistic effects that give any video a movie-like feel. With this co-engineering effort with ZEISS, vivo aims to equip users with all the tools they need to capture and edit professional-looking videos right from their smartphones. With a shared goal of creating premium technology and cutting-edge designs, vivo's strong understanding of consumer preferences and ZEISS' optical innovations can push for the high-quality development of mobile imaging technology that is best for consumers. The partnership continues to expand in new directions, such as exploring new lens materials, optical design, and optical simulations to bring more professional photography experiences to everyday life. The partnership recently expanded to vivo's V series smartphones for the first time with the launch of the new V30 Pro. Most known for its powerful portrait photography features and innovative Color, Material, and Finish (CMF) designs, the software and hardware innovations of V30 Pro allow creators to experience exceptional professional photography outside its flagship line. By setting a new benchmark in mobile imaging, vivo strengthens its commitment to believing that everyone can be a professional portrait creator. Setting a New Standard for Mobile Portrait Photography with V30 Pro The newest upgrades of V30 Pro best showcase the complementary expertise of vivo and ZEISS. The rear camera module of vivo V30 Pro features the ZEISS Triple Main Camera, which includes a 50 MP Professional Portrait Camera, a 50 MP AF Ultra Wide-Angle Camera, and a 50 MP VCS True Color Main Camera. Each camera meets ZEISS Optics standards, ensuring top-level quality. V30 Pro is the first smartphone with a 50 MP Professional Portrait Camera. Featuring a focal length of 50 mm, it can deliver portraits that are exceptionally vivid to closely align with the human eye's natural viewpoint. V30 Pro boasts four times the pixel count of the previous 12 MP portrait camera on V29 and features 2x zoom, ensuring the capturing of excellent portrait quality with exceptional clarity from a distance. In another V series' first, the 50 MP AF Ultra Wide-Angle Camera is equipped with Auto Focus that boasts 6.25 times the pixel count of any ordinary 8 MP wide-angle camera. It redefines the wide-angle experience with its 119-degree[1] Ultra Wide-Angle Perspective that is perfect for group photos. Complete with the 50 MP vivo VCS True Color Main Camera, V30 Pro features a vivo-exclusive Camera-Bionic Spectrum (VCS) that can enhance image clarity and color reproduction to increasingly resemble closer to what the human eye can see. Boasting a 1/1.49″ sensor, the largest in its series, the camera is also supported by Optical Image Stabilization, protecting users from shakiness and low-light conditions at night. vivo and ZEISS together decided to incorporate selected co-engineered features into V30 Pro, thereby elevating its portrait photography capabilities to a new level. Like in X series, users can now experience the iconic ZEISS Style Portraits for the first time on V series, too. Inspired by the renowned ZEISS lenses, V30 Pro features six distinct portrait bokeh styles: ZEISS Biotar, Sonnar, Planar, Distagon, Cinematic Style Bokeh and ZEISS Cine-flare Portrait. This gives the opportunity for creators to freely express their creativity and deliver vivid portraits best suited for their style. Creators can also showcase their inner cinephiles with the integration of the ZEISS Cinematic Video Bokeh. The ZEISS Cinematic Video Bokeh includes a unique aspect ratio of 2.39:1 for a more prominent look and feel with AI-based depth calculations for a natural bokeh effect. In post-production, users can also customize their color profiles using the vivo Color System. One option, the ZEISS Natural color, is designed to restore the colors of the image in their most authentic form -- ideal for professional users who prefer flexibility while editing. In addition to its co-engineering with ZEISS, vivo is also investing into its own R&D to create innovative new features for users. Distinct to V29 series, V30 Pro introduces a smarter lighting solution for studio-like portrait lighting on the go. The upgraded Aura Light Portrait feature, designed to capture high-quality shots in portrait photography, offers softer but more powerful lighting by creating a light-emitting area 19 times larger and 50 times softer compared to the standard flash.[2] With vivo V30 Pro, users can capture clear portraits even at night. What's more, V30 Pro features supporting software that can intelligently adjust the lighting temperature based on its surroundings. The Smart Color Temperature Adjustment can prevent issues such as color casting and blurring by intelligently adjusting color temperature. Distance-Sensitive Lighting means that V30 Pro can adjust the brightness level of Aura Light based on the subject's distance in real time with centimeter-level precision. vivo V30 Pro also ensures consistent fill light effect on the face, regardless of the shooting distance. As a leading technology brand, vivo's relentless pursuit of imaging excellence and its strategic partnerships are not just setting new standards in mobile photography, but also opening up possibilities for the future. This commitment to innovation ensures that no matter where technology trends take us, vivo will continue to deliver imaging technology that better serves its users. [1] The optical field of view of the 50 MP AF Ultra Wide-Angle Camera is 119°, and 109.2° after distortion correction. [2] The improvement data of the light-emitting area and softness comes from vivo's laboratory based on a comparison of the Aura Light and the flash on V30 Pro. About vivo vivo is a technology company that creates great products based on a design-driven value, with smart devices and intelligent services as its core. The company aims to build a bridge between humans and the digital world. Through unique creativity, vivo provides users with an increasingly convenient mobile and digital life. Following the company's core values, which include Benfen,* user-orientation, design-driven value, continuous learning and team spirit, vivo has implemented a sustainable development strategy with the vision of developing into a healthier, more sustainable world-class corporation. While bringing together and developing the best local talents to deliver excellence, vivo is supported by a network of R&D centers in Shenzhen, Dongguan, Nanjing, Beijing, Hangzhou, Shanghai and Xi'an, focusing on the development of state-of-the-art consumer technologies, including 5G, artificial intelligence, industrial design, imaging system and other up-and-coming technologies. vivo has also set up an intelligent manufacturing network (including those authorized by vivo), with an annual production capacity of nearly 200 million smartphones. As of now, vivo has branched out its sales network across more than 60 countries and regions, and is loved by more than 400 million users worldwide. *"Benfen" is a term describing the attitude on doing the right things and doing things right – which is the ideal description of vivo's mission to create value for society. Stay informed of latest vivo news at https://www.vivo.com/en/about-vivo/news
SINGAPORE - Media OutReach Newswire - 3 April 2024 - Following last year's resounding success, ICEX Spain, through the Economic and Commercial Office of the Spanish Embassy in Singapore, is excited to announce the launch of "Eat Spain Drink Spain Singapore 2024", a larger and more ambitious initiative to promote the exquisite and healthy Spanish cuisine in Singapore with 10 events of unique gastronomic experiences with Spanish flavour. This activity is going to be held between September the 15th and October the 15th. This year, with an increased budget, the campaign expands to 10 exclusive events including wine dinners, tastings, showcookings, culinary demonstrations, and joint promotions with renowned Food & Beverage companies in Singapore. These activities will highlight the richness and diversity of Spanish cuisine, globally recognized as a cornerstone of the exquisite and healthy Mediterranean diet, associated with one of the world's longest life expectancies. Moreover, this year's campaign places special emphasis on promoting the 18 Singaporean restaurants bearing the Restaurants From Spain (RFS) seal, a guarantee of authenticity and quality in Spanish cooking. Further details regarding participating restaurants and can be found on the restaurants' websites. Restaurant Address ASADOR 51 Joo Chiat Place, 427775 BINOMIO 20 Craig Road, Craig Place #01-02, 089692 ESQUINA 16 Jiak Chuan Road, 089267 FOC 40 Hongkong Street, 059679 FOC SENTOSA 110 Tanjong Beach Walk, 098943 GAIG 16 Stanley Street, 068735 KULTO 87 Amoy Street, 069906 LUMBRE 15 Mohamed Sultan Road, 238964 MY LITTLE SPANISH PLACE – BOAT QUAY 54 Boat Quay, 049843 MY LITTLE SPANISH PLACE – BUKIT TUMAH 619 Bukit Timah Road, 269720 NEXT DOOR SPANISH CAFÉ 699 East Coast Road, 459061 OLIVIA RESTAURANT & LOUNGE 55 Keong Saik Road, #01-03, 089158 UNA at the Alkaff Mansion 10 Telok Blangah Green, 109178 TAPAS 24 60 Robertson Quay, #01-04, 238252 TAPAS CLUB VIVO CITY 1 Harbourfront Walk, #01-98/99, 098585 TAPAS CLUB ORCHARD 181 Orchard Road, #02-13/15 238896 TAPAS CLUB JEWEL 78 Airport Boulevard, Jewel Changi Airport, #03-220/221/222, 819666 PURA BRASA 5 Wallich Street, #01-16, Guoco Tower, 078883 With the purpose of strengthening cultural and commercial ties between Spain and Singapore, "Eat Spain, Drink Spain 2024" campaign invites everyone to explore and enjoy the unparalleled culinary experience offered by Spanish cuisine. For more information about the campaign, check this link about last year's Eat Spain, Drink Spain (ESDS).Hashtag: #EATSPAINDRINKSPAIN #FOOD #RESTAURANTS #RESTAURANTSFROMSPAIN #RFS #SPANISHFOOD #CULINARYEXPERIENCEhttps://www.icex.es/es/quienes-somos/donde-estamos/red-exterior-de-comercio/SG/iniciohttps://www.linkedin.com/company/99292369/admin/feed/posts/https://www.foodswinesfromspain.com/en/upcoming-events/trade-shows-detail-four/eat-spain--drink-spain-2023The issuer is solely responsible for the content of this announcement."Restaurants from Spain (RFS)"The "Restaurants from Spain" certificate is an instrument for the support and recognition of restaurant initiatives that are focused on Spanish cuisine and, by extension, the Spanish culture, guaranteeing the level of quality of these establishments. It recognizes and establishes quality standards and criteria for the consumer who is looking for quality Spanish cuisine, as well as models that can be followed by restaurateurs who may wish to offer Spanish cuisine in other parts of the world. All the restaurants that have the "Restaurants from Spain" certificate will share a feeling of Spanish gastronomy based on genuine roots, ingredients, recipes, and quality. Awarded following a stringent selection process by a joint committee composed of official institutions and sectoral associations, chaired by ICEX Spain Trade and Investment, strongly linked to gastronomy such as the Royal Academy of Gastronomy, the Ministry of Agriculture, the Regulatory Council for Jérez-Xérès-Sherry Wines D.O.P., INTERPORC, ASTUREX, the Spanish Wine Federation, Spanish Olive Oils Interprofessional and the REPSOL Guide,[MS1] the certificate will distinguish those establishments that outside Spain offer their diners not only Spanish products but also authentic quality Spanish cuisine, with a unique and differentiated image. The certification, which will be renewed annually, will have a direct and immediate impact on the HORECA channel, whose activity has been severely affected by the pandemic, by promoting greater knowledge of the restaurant in the country, boosting its occupation, and the dissemination of authentic quality Spanish cuisine. Besides the certification, the restaurant's team will receive specialized training in both gastronomy and Spanish wines, thus being able to expand the Spanish culinary offer available on the menu. And in parallel, the certificate will facilitate access to the restaurant, and therefore to the market, to a greater number of suppliers of Spanish products, which will boost the presence of Spanish food and wine around the world.
A12 藝術空間
vivo
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
